Brokerages Set Janux Therapeutics, Inc. (NASDAQ:JANX) PT at $66.29

Janux Therapeutics, Inc. (NASDAQ:JANX) has been assigned an average recommendation of “Moderate Buy” from the eight research firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $66.29.

A number of brokerages recently commented on JANX. HC Wainwright boosted their target price on shares of Janux Therapeutics from $50.00 to $63.00 and gave the stock a “buy” rating in a research note on Monday, May 13th. Scotiabank started coverage on shares of Janux Therapeutics in a research note on Thursday, May 30th. They issued a “sector perform” rating and a $47.00 price objective for the company. Wedbush upped their price objective on shares of Janux Therapeutics from $53.00 to $74.00 and gave the company an “outperform” rating in a research note on Wednesday, May 8th. Jonestrading started coverage on shares of Janux Therapeutics in a research note on Tuesday, April 16th. They issued a “buy” rating and a $70.00 price objective for the company. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $100.00 price objective on shares of Janux Therapeutics in a research note on Thursday, May 9th.

Insider Buying and Selling

In related news, Director Jay Lichter sold 1,500,000 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $54.75, for a total transaction of $82,125,000.00. Following the sale, the director now owns 633,673 shares in the company, valued at $34,693,596.75. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Janux Therapeutics news, Director Jay Lichter sold 1,500,000 shares of Janux Therapeutics stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $54.75, for a total value of $82,125,000.00. Following the transaction, the director now owns 633,673 shares in the company, valued at approximately $34,693,596.75. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Ventures Xi L.P. Avalon sold 677,279 shares of Janux Therapeutics stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $54.75, for a total transaction of $37,081,025.25. Following the completion of the transaction, the insider now owns 3,271,216 shares in the company, valued at approximately $179,099,076. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 3,000,000 shares of company stock worth $164,250,000. 35.40% of the stock is owned by insiders.

Institutional Trading of Janux Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC boosted its position in Janux Therapeutics by 10,740.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,710 shares of the company’s stock worth $29,000 after purchasing an additional 2,685 shares during the period. Summit Securities Group LLC purchased a new stake in Janux Therapeutics during the 2nd quarter worth $29,000. China Universal Asset Management Co. Ltd. acquired a new position in Janux Therapeutics in the 4th quarter worth $57,000. SG Americas Securities LLC acquired a new position in Janux Therapeutics in the 4th quarter worth $100,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Janux Therapeutics in the 2nd quarter worth $151,000. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Trading Down 1.1 %

Shares of JANX stock opened at $41.23 on Wednesday. The firm has a fifty day moving average price of $43.46 and a 200 day moving average price of $37.12. The company has a market cap of $2.14 billion, a P/E ratio of -33.79 and a beta of 3.58. Janux Therapeutics has a 12 month low of $5.65 and a 12 month high of $65.60.

Janux Therapeutics (NASDAQ:JANX) last issued its earnings results on Tuesday, May 7th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.05. The firm had revenue of $1.25 million during the quarter, compared to the consensus estimate of $0.98 million. Janux Therapeutics had a negative net margin of 762.92% and a negative return on equity of 13.49%. On average, equities analysts forecast that Janux Therapeutics will post -1.34 EPS for the current year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.